Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its target price dropped by research analysts at Robert W. Baird from $58.00 to $50.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 164.55% from the company’s previous close.

DNTH has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Tuesday. Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $53.00.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $18.90 on Tuesday. Dianthus Therapeutics has a one year low of $13.37 and a one year high of $32.27. The stock’s fifty day moving average is $19.58 and its 200 day moving average is $22.27. The stock has a market cap of $607.18 million, a P/E ratio of -7.56 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.81 million. Analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DNTH. Barclays PLC grew its position in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after purchasing an additional 814 shares in the last quarter. KBC Group NV purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $35,000. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $26,000. Finally, Rhumbline Advisers grew its position in shares of Dianthus Therapeutics by 3.8% during the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company’s stock valued at $783,000 after purchasing an additional 1,316 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.